menu
    • menu

    Company profile for Novartis Pharmaceuticals Corporation

    NEW Drugs in Dev: 450
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals ...
    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals Corporation, we believe that all Americans deserve access to quality health care, including prescription medicines, health education about their disease or condition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novartis Pharmaceuticals CorporationSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Argo Biopharma Doses First Patient in BW-50218 Phase 1 Trial
    Argo Biopharma Doses First Patient in BW-50218 Phase 1 Trial

    28 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/argo-biopharma-announces-first-subject-dosed-in-phase-i-study-of-sirna-therapeutic-bw-50218-302755606.html

    PR NEWSWIRE
    28 Apr 2026
    Share Share
    Novartis CEO Concerned About Germany's €60B Healthcare Spending
    Novartis CEO Concerned About Germany's €60B Healthcare Spending

    28 Apr 2026

    // ENDPOINTS

    https://endpoints.news/novartis-ceo-disheartened-by-germanys-planned-e60b-cuts-to-healthcare-spending/

    ENDPOINTS
    28 Apr 2026
    Share Share
    Novartis Posts Strong Q1 Growth, Reaffirms 2026 Guidance
    Novartis Posts Strong Q1 Growth, Reaffirms 2026 Guidance

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282207/0/en/novartis-delivered-strong-growth-in-priority-brands-and-launches-in-q1-fy-2026-guidance-reaffirmed.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    PTC Therapeutics To Share PIVOT-HD Study Long-Term Results
    PTC Therapeutics To Share PIVOT-HD Study Long-Term Results

    28 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ptc-therapeutics-to-report-results-from-pivot-hd-long-term-extension-study-302755766.html

    PR NEWSWIRE
    28 Apr 2026
    Share Share
    Novartis Highlights First Quarter Earnings Call
    Novartis Highlights First Quarter Earnings Call

    28 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7237311

    FIRSTWORD PHARMA
    28 Apr 2026
    Share Share
    Novartis Reports Earnings Miss Due To Generic Competition
    Novartis Reports Earnings Miss Due To Generic Competition

    28 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-q1-profit-down-us-generic-erosion-2026-04-28/

    REUTERS
    28 Apr 2026
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Pentetreotide

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Pentetreotide

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 9906

    Submission : 1992-10-09

    Status : Active

    Type : II

     CEP/COS JDMF arrow-down
    ✖

    Registration Number : 227MF10097

    Registrant's Address : Lichtstrasse 35, CH-4056 Basel, Switzerland

    Initial Date of Registration : 2015-04-09

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Sertraline Hydrochloride

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Sertraline Hydrochloride

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 42608

    Submission : 2025-09-26

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2008-304 - Rev 05

    Issue Date : 2025-09-30

    Type : Chemical

    Substance Number : 1705

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 84206-0116

    Start Marketing Date : 2025-10-06

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (10kg/10kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Valsartan

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Valsartan

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23902

    Submission : 2010-07-02

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2016-290 - Rev 03

    Issue Date : 2024-10-16

    Type : Chemical

    Substance Number : 2423

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Novartis Korea

    Registration Date : 2011-12-09

    Registration Number : 20111209-135-H-172-28

    Manufacturer Name : Novartis Grimsby Ltd.

    Manufacturer Address : Moody Lane, Pyewipe, Grimsby_N.E. Lincolnshire/DN31 2SR/England

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Nevirapine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Nevirapine

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 25221

    Submission : 2011-08-22

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2011-075 - Rev 06

    Issue Date : 2025-09-15

    Type : Chemical

    Substance Number : 2255

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Zidovudine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Zidovudine

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF Inactive-api
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 25082

    Submission : 2011-06-17

    Status : Inactive

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2007-318 - Rev 07

    Issue Date : 2025-09-30

    Type : Chemical

    Substance Number : 1059

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 84206-0104

    Start Marketing Date : 2024-08-26

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Cabotegravir Sodium

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Cabotegravir Sodium

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 41842

    Submission : 2025-09-29

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Fluvastatin

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Fluvastatin

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 23901

    Submission : 2010-06-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Lutetium Chloride Lu-177

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Lutetium Chloride Lu-177

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 31705

    Submission : 2017-05-02

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    NAFTIFINE HCL

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    NAFTIFINE HCL

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 16772

    Submission : 2003-08-19

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Terbinafine

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PCC
    Not Confirmed
    arrow

    Terbinafine

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 27059

    Submission : 2013-06-07

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : GP Therapeutics Korea Co., Ltd.

    Registration Date : 2011-02-15

    Registration Number : 20110215-49-A-244-16

    Manufacturer Name : Novartis Ringaskiddy Limited

    Manufacturer Address : Ringaskiddy, Co. Cork

     VMF Others AUDIT
    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

    Details:

    Pelacarsen is a oligonucleotide drug, which is currently being evaluated in Phase III clinical studies for the treatment of cardiovascular diseases.


    Lead Product(s): Pelacarsen

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 08, 2026

    blank

    01

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pelacarsen

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term ...

    Details : Pelacarsen is a oligonucleotide drug, which is currently being evaluated in Phase III clinical studies for the treatment of cardiovascular diseases.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    April 08, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis to Acquire Excellergy, Inc. for Next-Gen Anti-IgE Innovation

    Details:

    Under the acquisition of Exl-111, an unconjugated antibody targeting IgE, the deal aims to advance treatments for allergic disease.


    Lead Product(s): Exl-111

    Therapeutic Area: Immunology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody, Unconjugated

    Recipient: Excellergy

    Deal Size: $2,000.0 million Upfront Cash: Undisclosed

    Deal Type: Acquisition March 27, 2026

    blank

    02

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Exl-111

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Recipient : Excellergy

    Deal Size : $2,000.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis to Acquire Excellergy, Inc. for Next-Gen Anti-IgE Innovation

    Details : Under the acquisition of Exl-111, an unconjugated antibody targeting IgE, the deal aims to advance treatments for allergic disease.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    March 27, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

    Details:

    Atrasentan is a Miscellaneous drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Glomerulonephritis, IGA.


    Lead Product(s): Atrasentan

    Therapeutic Area: Nephrology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 27, 2026

    blank

    03

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Atrasentan

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric...

    Details : Atrasentan is a Miscellaneous drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Glomerulonephritis, IGA.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 27, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

    Details:

    NIO752 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Supranuclear Palsy, Progressive.


    Lead Product(s): NIO752

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Oligonucleotide

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 27, 2026

    blank

    04

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NIO752

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

    Details : NIO752 is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Supranuclear Palsy, Progressive.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : Inapplicable

    March 27, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blasti...

    Details:

    Asciminib is a Miscellaneous drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.


    Lead Product(s): Asciminib,Imatinib Mesylate,Dasatinib,Nilotinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Recipient: University of Hong Kong

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 25, 2026

    blank

    05

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Asciminib,Imatinib Mesylate,Dasatinib,Nilotinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : University of Hong Kong

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Tran...

    Details : Asciminib is a Miscellaneous drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 25, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

    Details:

    Secukinumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Hidradenitis Suppurativa.


    Lead Product(s): Secukinumab

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 24, 2026

    blank

    06

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Secukinumab

    Therapeutic Area : Dermatology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidr...

    Details : Secukinumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Hidradenitis Suppurativa.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    March 24, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor for Breast Cancer Pipeline

    Details:

    Under the acquisition of SNV4818, targeting PI3K-alpha, the deal aims to advance treatment for HR+/HER2- breast cancer.


    Lead Product(s): SNV4818

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Recipient: Synnovation Therapeutics

    Deal Size: $3,000.0 million Upfront Cash: $2,000.0 million

    Deal Type: Acquisition March 20, 2026

    blank

    07

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : SNV4818

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Recipient : Synnovation Therapeutics

    Deal Size : $3,000.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor for Breast Cancer Pipeline

    Details : Under the acquisition of SNV4818, targeting PI3K-alpha, the deal aims to advance treatment for HR+/HER2- breast cancer.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : $2,000.0 million

    March 20, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

    Details:

    HJB647 is currently being evaluated in Phase I clinical studies for the treatment of heart failure, systolic.


    Lead Product(s): HJB647

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 12, 2026

    blank

    08

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : HJB647

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Frac...

    Details : HJB647 is currently being evaluated in Phase I clinical studies for the treatment of heart failure, systolic.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    March 12, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

    Details:

    GXV813 is currently being evaluated in Phase II clinical studies for the treatment of schizophrenia.


    Lead Product(s): GXV813

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Undisclosed

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 12, 2026

    blank

    09

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GXV813

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults ...

    Details : GXV813 is currently being evaluated in Phase II clinical studies for the treatment of schizophrenia.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    March 12, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other S...

    Details:

    JDQ443 (Opnurasib) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of carcinoma, non-small-cell lung.


    Lead Product(s): JDQ443,TNO155,Trametinib,Cetuximab,Tislelizumab

    Therapeutic Area: Oncology Brand Name: JDQ443

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 12, 2026

    blank

    10

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    PCC
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : JDQ443,TNO155,Trametinib,Cetuximab,Tislelizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnu...

    Details : JDQ443 (Opnurasib) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of carcinoma, non-small-cell lung.

    Product Name : JDQ443

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 12, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Novartis Pharmaceuticals Corporation and get a quotation

    Novartis Pharmaceuticals Corporation is a supplier offers 72 products (APIs, Excipients or Intermediates).

    Find Pentetreotide bulk with DMF, JDMF offered by Novartis Pharmaceuticals Corporation

    Find Valsartan bulk with DMF, CEP offered by Novartis Pharmaceuticals Corporation

    Find Amlodipine Besylate bulk with CEP offered by Novartis Pharmaceuticals Corporation

    Find Baclofen bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find Cyclosporine bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find Fluvastatin bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find Glycolide - lactide copolymer bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find Letrozole bulk with CEP offered by Novartis Pharmaceuticals Corporation

    Find NAFTIFINE HCL bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find Terbinafine bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find Topotecan Hydrochloride bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find Benzonatate bulk offered by Novartis Pharmaceuticals Corporation

    Find Bisoctrizole bulk offered by Novartis Pharmaceuticals Corporation

    Find Chlorthalidone bulk offered by Novartis Pharmaceuticals Corporation

    Find Clofazimine bulk offered by Novartis Pharmaceuticals Corporation

    Find Clomipramine Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find Edotreotide bulk offered by Novartis Pharmaceuticals Corporation

    Find Eudragit Rs bulk offered by Novartis Pharmaceuticals Corporation

    Find Methylphenidate Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find Naphazoline Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find Pyrilamine bulk offered by Novartis Pharmaceuticals Corporation

    Find Pyrilamine Maleate bulk offered by Novartis Pharmaceuticals Corporation

    Find Rifampicin bulk offered by Novartis Pharmaceuticals Corporation

    Find Thurfyl Nicotinate bulk offered by Novartis Pharmaceuticals Corporation

    Find TESSALON DRUG SUBSTANCE bulk offered by Novartis Pharmaceuticals Corporation

    Find CGP 17,582B bulk offered by Novartis Pharmaceuticals Corporation

    Find PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by Novartis Pharmaceuticals Corporation

    Find 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by Novartis Pharmaceuticals Corporation

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by Novartis Pharmaceuticals Corporation

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by Novartis Pharmaceuticals Corporation

    Find ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by Novartis Pharmaceuticals Corporation

    Find PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by Novartis Pharmaceuticals Corporation

    Find TINUVIN 326 bulk offered by Novartis Pharmaceuticals Corporation

    Find FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by Novartis Pharmaceuticals Corporation

    Find STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by Novartis Pharmaceuticals Corporation

    Find CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by Novartis Pharmaceuticals Corporation

    Find PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by Novartis Pharmaceuticals Corporation

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by Novartis Pharmaceuticals Corporation

    Find Alpelisib bulk offered by Novartis Pharmaceuticals Corporation

    Find Asciminib bulk offered by Novartis Pharmaceuticals Corporation

    Find Atorvastatin bulk offered by Novartis Pharmaceuticals Corporation

    Find Dabrafenib Mesylate bulk offered by Novartis Pharmaceuticals Corporation

    Find Deferasirox bulk offered by Novartis Pharmaceuticals Corporation

    Find Diclofenac Diethylamine bulk offered by Novartis Pharmaceuticals Corporation

    Find Eltrombopag bulk offered by Novartis Pharmaceuticals Corporation

    Find Everolimus bulk offered by Novartis Pharmaceuticals Corporation

    Find Fingolimod Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find Fluvastatin Sodium bulk offered by Novartis Pharmaceuticals Corporation

    Find Hydrochlorothiazide bulk offered by Novartis Pharmaceuticals Corporation

    Find Imatinib Mesylate bulk offered by Novartis Pharmaceuticals Corporation

    Find Inclisiran bulk offered by Novartis Pharmaceuticals Corporation

    Find Indacaterol Maleate bulk offered by Novartis Pharmaceuticals Corporation

    Find Iptacopan Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find Ketotifen Fumarate bulk offered by Novartis Pharmaceuticals Corporation

    Find Lithium Carbonate bulk offered by Novartis Pharmaceuticals Corporation

    Find Mycophenolate Mofetil bulk offered by Novartis Pharmaceuticals Corporation

    Find Mycophenolate Sodium bulk offered by Novartis Pharmaceuticals Corporation

    Find Nilotinib bulk offered by Novartis Pharmaceuticals Corporation

    Find Osilodrostat Phosphate bulk offered by Novartis Pharmaceuticals Corporation

    Find Oxcarbazepine bulk offered by Novartis Pharmaceuticals Corporation

    Find Pimecrolimus bulk offered by Novartis Pharmaceuticals Corporation

    Find Ribociclib bulk offered by Novartis Pharmaceuticals Corporation

    Find Rivastigmine bulk offered by Novartis Pharmaceuticals Corporation

    Find Rivastigmine Tartrate bulk offered by Novartis Pharmaceuticals Corporation

    Find Sacubitril-Valsartan bulk offered by Novartis Pharmaceuticals Corporation

    Find Siponimod bulk offered by Novartis Pharmaceuticals Corporation

    Find Tacrolimus bulk offered by Novartis Pharmaceuticals Corporation

    Find Terbinafine Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find Trametinib bulk offered by Novartis Pharmaceuticals Corporation

    Find Valsartan bulk offered by Novartis Pharmaceuticals Corporation

    Find Vildagliptin bulk offered by Novartis Pharmaceuticals Corporation

    Find BASILIXIMAB bulk offered by Novartis Pharmaceuticals Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search